Ipca Labs on strong growth path: Why this pharma company is stock pick of the week

Ipca Labs, a mid-sized pharma company continues to report good numbers and its results for the third quarter of 2020-21 were no different. The y-o-y growth on its consolidated revenues and net profit was 16% and 34% respectively. Analysts are getting bullish on this counter now because they feel that Ipca will be able to report better results in the coming years owing to several factors.Ipca continues to do well in the domestic market and is